References
  1. John ATS, Stuart KA, Crawford DHG. Testing for HFE-related haemochromatosis. Aust Prescr 2011; 34:73-6. doi: 10.18773/austprescr.2011.046
  2. Nicholas C. P. Cross; Genetic and Epigenetic Complexity in Myeloproliferative Neoplasms. Hematology Am Soc Hematol Educ Program  2011; 2011 (1): 208–214. doi: 10.1182/asheducation-2011.1.208. PMID: 22160036.
  3. Cuthbert D, Stein BL. Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Manifestations, And Effects On Outcomes. J Blood Med. 2019 Oct 18; 10:359-371. doi:10.2147/JBM.S189922
  4. Daniel A. Arber, Attilio Orazi, Robert Hasserjian, Jürgen Thiele, Michael J. Borowitz, Michelle M. Le Beau, Clara D. Bloomfield, Mario Cazzola, James W. Vardiman; The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood  2016; 127 (20): 2391–2405. doi: 10.1182/blood-2016-03-643544
  5. Prevalence of HFE genotypes, C282Y and H63D, in patients with hematologic disorders. Hannuksela J, Savolainen ER, Koistinen P, Parkkila S. Haematologica. 2002 Feb;87(2):131-5. doi: 10.3324/%25x
  6. Franchini M, de Matteis G, Federici F, Solero P, Veneri D. Analysis of hemochromatosis gene mutations in 52 consecutive patients with polycythemia vera. Hematology. 2004 Oct-Dec;9(5-6):413-4. doi: 10.1080/10245330400001934. PMID: 15763983.
  7. Prabhsimranjot Singh, Sudhamshi Toom, Makardhwaj S Shrivastava, William B. Solomon; A Rare Combination of Genetic Mutations in an Elderly Female: A Diagnostic Dilemma!. Blood 2016; 128 (22): 5487. doi: 10.1182/blood.V128.22.5487.5487